EligibleTrials

Biomarkers for Risk Stratification in Lung Cancer

Recruiting · NCT03774758 · Observational (researchers observe without assigning treatment) · Lead sponsor: University of California, San Francisco

View the official record on ClinicalTrials.gov →
Lung cancer

Interventions studied

Guardant Health ct-DNA LUNAR assay

What this trial is about

This is a prospective observational study that will follow patients who undergo lung cancer screening at the San Francisco VA Medical Center, University of California, San Francisco (UCSF) Medical Center, and the San Francisco General Hospital. The proposed study will comprise of two primary populations to determine the ctDNA assay performance in a variety of clinical settings.

Who can take part

Age range
40 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)

Inclusion criteria

Exclusion criteria

Where it is running

3 locations listed across 1 US state.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.